US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

argenx SE - American Depositary Shares (NQ:ARGX)

919.21 -16.79 (-1.79%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
What 25 Analyst Ratings Have To Say About argenx ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: argenx In The Eyes Of 27 Experts ↗
 
Via Benzinga
News headline image
Breaking Down argenx: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
News headline image
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
News headline image
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
News headline image
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
From argenx SE
Via GlobeNewswire
News headline image
Why Is European Drugmaker Argenx Stock Trading Higher On Monday? ↗
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
Via Benzinga
News headline image
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval ↗
This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
Via Investor's Business Daily
News headline image
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
News headline image
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
News headline image
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump ↗
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
News headline image
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 ↗
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2024 Health Care Conference
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >